There are provided methods and systems for detecting and/or quantifying an analyte. In particular, there are provided methods and systems for simultaneous detection and/or quantitation of two or more analytes in a sample. Colocalization-by-linkage assays on microparticles (CLAMP) can be engineered and used to effectively multiplex the detection of analytes within a sample. Features and methods of CLAMP systems can provide robust and scalable analysis of analytes in a sample.

Described herein are Dirofilarial exhalant signatures and methods of detecting a Dirofilaria signature in a non-blood biological sample, such as exhalant, that can be used to detect Dirofilarial infection in a subject, such as a canine.

The present disclosure is directed to spherical nucleic acids (SNAs) comprising a nanoparticle core and an oligonucleotide, use of the SNAs to, e.g., detect target analytes, and methods of making the SNAs. In various embodiments, the target analyte is detected using the nanoparticle core, the oligonucleotide, or both. In some embodiments, the oligonucleotide comprises a detectable marker situated at an internal location within the oligonucleotide. In some aspects, the disclosure provides methods for detecting a target analyte comprising the step of contacting the target analyte with a spherical nucleic acid (SNA) and an agent, the SNA comprising a protein core and an oligonucleotide attached thereto, wherein the contacting of the protein core with the target analyte results in a change in the target analyte that is detectable by the agent, thereby detecting the target analyte.

The present invention provides a nucleic acid aptamer specifically recognizing 3-lactoglobulin and use thereof. The nucleic acid aptamer has a sequence as shown in SEQ ID NO:1, a sequence having 60% or higher homology to the sequence as shown in SEQ ID NO:1 and specifically recognizing β-lactoglobulin, or a sequence derived from the sequence as shown in SEQ ID NO:1 and specifically recognizing β-lactoglobulin. The nucleic acid aptamer specifically binds to the allergen β-lactoglobulin in cow milk and dairy products, thereby providing a new tool for the high-sensitivity and low-cost detection of the allergen β-lactoglobulin.

The invention relates to a method for determining the florescence of antibodies on exosomes using quality control of the measurement using two different control methods.

The present invention features a method for solubilizing chitin in an aqueous solution by dissolving a sample containing chitin in a basic solution and autoclaving the sample. The present invention also features a method for quantifying the amount of chitin in a sample. Chitin binding proteins are used to quantify the amount of chitin using a modified ELISA assay. Results of the assay may be compared to a control containing known amounts of chitin to quantify the chitin in the sample.

Described herein is a method of preparing a bifunctional assay surface. In particular, a method is provided for preparing an assay surface that includes a primary reagent and a secondary reagent. In one aspect, the primary and secondary reagents are immobilized on the assay surface by different surface chemistries. In one aspect, a method is provided for preparing an assay surface that includes a proteinaceous primary reagent and a thiol-containing secondary reagent. In one aspect, a method is provided for preparing an assay surface that includes a capture-target hybrid and a thiol-containing secondary reagent.

A field apparatus (also referred to as a “biosampler”) is configured to automatically capture multiple samples of an aqueous medium (for example, water from a lake) and process same to preserve unstable analytes in the field. In this way, a set of samples from the aqueous medium can, for example, be captured at multiple points in time, processed with a biopreservative to preserve unstable analytes (for example, RNA) and then later collected for further analysis. Alternatively, multiple samples of the aqueous medium can be collected and preserved at one moment.

The present invention relates to a system and methods for evaluating and tracking the operation of the menstrual cycle and treating undesirable trends associated with the menstrual cycle. Various aspects of the system and methods described herein rely upon the operation of diagnostic tests specially configured to evaluate a bodily fluid for the presence or absence of hormones or analytes, and more specifically configured to evaluate a bodily fluid for at least the presence or absence of pregnanediol glucuronide at a threshold selected from the range inclusive of 1 μg/mL-10 μg/mL. The results from one or more diagnostic tests are interpreted in accordance with the teachings of the system. The interpretations are useful in accordance with facilitating treatments associated with medical conditions correlated to the generated interpretations, optionally delivered during a consultation with a medical provider during a telemedicine consultation, the treatments optionally comprising dietary changes incorporating the consumption of certain seeds to mitigate hormonal imbalances.

Methods described herein include receiving data from flowing a plurality of aptamers over a sample of tumor cells randomly affixed to a surface of a microfluidic device. The tumor cells may include one or more unknown tumor subtypes of cells. The plurality of aptamers may include a plurality of aptamer families. Each aptamer family of the plurality of aptamer families may be determined to bind to at least one possible subtype of the tumor cells. The data may include a measure of binding affinity of each aptamer family to the tumor cells. The method may include analyzing the measure of the binding affinity of each aptamer family to the tumor cells. The analyzing may include classifying the binding affinity. The method may also include determining one or more aptamer families that characterize the one or more unknown tumor subtypes of cells based on the classifying.